Companies in #Solid tumors
Found 4 companies operating in this sector.
Clinical-stage biopharmaceutical company (NASDAQ: CNTX) advancing medicines for solid tumors, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody. In August 2026 the company discontinued its bispecific program to extend its cash runway into 2027.
GT Biopharma (NASDAQ: GTBP) is a clinical-stage immuno-oncology company headquartered in San Francisco, California, developing natural killer (NK) cell engager therapeutics built on its Tri-specific Killer Engager (TriKE) and dual-targeting Tetra-specific Killer Engager platforms. Its lead program, GTB-3650, is in Phase 1 development against CD33-expressing myeloid leukemias; GTB-5550 is in a Phase 1 dose-escalation basket trial in B7-H3-positive advanced solid tumors; and GTB-7550 is a preclinical candidate for lupus and other autoimmune disorders. The company was incorporated in 1965, was formerly known as OXIS International, and adopted the GT Biopharma name in July 2017. On September 11, 2026, shares rose 39.32% on volume 11.49 times the 30-day average as the company hosted a live presentation on the TriKE platform and its clinical progress, against roughly $5.1 million of cash and equivalents at June 30, 2026 and company guidance that runway extends through the fourth quarter of 2026.
Intensity Therapeutics is a late-stage clinical biotechnology company developing intratumoral cancer therapies designed to address both the regional and systemic nature of cancer relapse and metastasis. Its lead product candidate, INT230-6, combines active anti-cancer agents with amphiphilic molecules using the company's proprietary DfuseRx non-covalent conjugation technology; it is in Phase 3 clinical studies for soft tissue sarcoma and in Phase 2 trials for neoadjuvant and metastatic triple-negative breast cancer. Incorporated in 2012, the company is headquartered in Shelton, Connecticut and listed on Nasdaq in June 2023.
Commercial-stage biopharmaceutical company (NASDAQ: IOVA) developing and commercializing autologous tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead product Amtagvi (lifileucel) is an individualized T cell therapy approved for previously treated advanced or unresectable or metastatic melanoma, marketed alongside Proleukin (interleukin-2). The pipeline extends lifileucel into cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma, with next-generation programs including LN-145, IOV-2001, IOV-4001, and IOV-3001. Q2 2026 product revenue of $99.3 million (up from $59 million a year earlier) powered a roughly 43% single-day gain and a new 52-week high in August 2026.